Champions Oncology (CSBR) director reports 8,032 stock options granted

Rhea-AI Filing Summary

Champions Oncology, Inc. director Robert Lawrence Brainin filed an initial ownership report showing a stock option holding. He holds an option to purchase 8,032 shares of common stock at an exercise price of $9.27 per share, expiring on June 9, 2031. The option vests over a two‑month period, with 6,024 options vesting on June 9, 2021 and 2,008 options vesting on August 9, 2021, and is held directly.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Brainin Robert Lawrence

(Last) (First) (Middle)

C/O CHAMPIONS ONCOLOGY, INC

ONE UNIVERSITY PLAZA, SUITE 307

(Street)

HACKENSACK NJ 07601

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/09/2021

3. Issuer Name and Ticker or Trading Symbol
CHAMPIONS ONCOLOGY, INC. [ CSBR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase Common Stock	(1)	06/09/2031	Common Stock	8,032	$9.27	D

Explanation of Responses:

1. The options vest and are exercisable over a two month period, with vesting for 6,024 options to occur on June 9, 2021 and 2,008 options to occur on August 9, 2021.

Remarks:

	/s/ Robert L. Brainin	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider position did Robert Lawrence Brainin report at Champions Oncology (CSBR)?

Robert Lawrence Brainin, a director of Champions Oncology, Inc., reported holding an option to purchase 8,032 shares of the company’s common stock.

What are the key terms of the stock option reported by the Champions Oncology (CSBR) director?

The reported derivative is an option to purchase 8,032 shares of common stock at an exercise price of $9.27 per share, expiring on June 9, 2031.

How does the stock option for the Champions Oncology (CSBR) director vest?

The option vests over a two‑month period, with 6,024 options vesting on June 9, 2021 and 2,008 options vesting on August 9, 2021.

Is the reported Champions Oncology (CSBR) stock option held directly or indirectly?

The option to purchase 8,032 shares of Champions Oncology common stock is reported as held directly by Robert Lawrence Brainin.

What type of SEC form did the Champions Oncology (CSBR) director file?

Robert Lawrence Brainin filed a Form 3, which is an initial statement of beneficial ownership of securities for insiders such as directors.